In this paper, we describe 141 germline variants in the BRCA1 and BRCA2 promoter, identified by members of the ENIGMA consortium in early onset or familial BC patients with no known pathogenic variants in the coding region of these genes. This evidence concerns the gene BRCA2 and breast cancer.